Literature DB >> 23856214

Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation.

Marion Tible1, Alexandre Loupy, Dewi Vernerey, Caroline Suberbielle, Thibaut Beuscart, Aurelie Cazes, Romain Guillemain, Catherine Amrein, Veronique Pezzella, Jean-Noel Fabiani, Dominique Nochy, Gary Hill, Jean-Philippe Empana, Xavier Jouven, Dominique Charron, Patrick Bruneval, Jean-Paul Duong Van Huyen.   

Abstract

BACKGROUND: Humoral immune responses during heart transplantation may result in antibody-mediated rejection (AMR), which is now taken into account on endomyocardial biopsy (EMB) specimens and ranked according to the pathologic AMR (pAMR) grades of the International Society for Heart and Lung Transplantation classification. This classification might benefit from new immunohistological markers and validation by others biomarkers, namely donor-specific antibodies (DSA).
METHODS: From the 293 protocol EMBs performed in 113 patients in our institution during a 1-year period for this prospective study, 280 EMB specimens were available with both histology and immunohistochemistry. C4d and labeling of intravascular cells by cluster of differentiation (CD) 68 were performed on paraffin sections. Available sera (n = 150) concomitant of EMB specimens were tested for the presence of DSA. All of the pAMR+ EMB specimens, along with a set of randomized pAMR0 EMB specimens, were immunolabeled for mammalian target of rapamycin (mTOR) effectors, phosphorylated 70 S6-kinase (p70S6K) and phosphorylated S6 ribosomal protein (pS6RP).
RESULTS: AMR was diagnosed in 37 EMB specimens (13.2%): 1 pAMR1(I+), 27 pAMR1(H+), and 9 pAMR2. The proportion of DSA-positive EMB varied according to the pAMR grade, with pAMR0, pAMR1(H+), and pAMR2 EMB presenting 17.6%, 77.3%, and 100% of DSA-positivity, respectively. Among the 30 pAMR+ specimens with available DSA testing and the 30 pAMR0 randomized specimens, mTOR pathway immunohistochemistry showed endothelial cell positivity for p70S6K in 17 pAMR+ EMB specimens (56.7%) and in 1 pAMR0 EMB specimen (3.3%). pS6RP was detected in 8 pAMR+ EMB specimens (26.7%) and in 1 pAMR0 EMB specimen (3.3%).
CONCLUSIONS: p70S6K and pS6RP immunohistochemistry afford new markers of AMR on EMB specimens because their expression is correlated with microcirculation inflammation and DSA. The correlation of DSA with pAMR grade suggests that this grading system is valid.
Copyright © 2013 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibody-mediated rejection; donor-specific antibodies; endomyocardial biopsy; heart transplantation; microcirculation inflammation; pAMR

Mesh:

Substances:

Year:  2013        PMID: 23856214     DOI: 10.1016/j.healun.2013.05.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  20 in total

1.  Influence of HLA Mismatching on Survival in Lung Transplantation.

Authors:  Don Hayes; Bryan A Whitson; Samir N Ghadiali; Joseph D Tobias; Heidi M Mansour; Sylvester M Black
Journal:  Lung       Date:  2015-07-29       Impact factor: 2.584

2.  Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Curr Transplant Rep       Date:  2015-05-24

Review 3.  Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.

Authors:  Nicole M Valenzuela; Jeffrey T McNamara; Elaine F Reed
Journal:  Curr Opin Organ Transplant       Date:  2014-02       Impact factor: 2.640

Review 4.  The role of complement in antibody mediated transplant rejection.

Authors:  Joshua M Thurman; Sarah E Panzer; Moglie Le Quintrec
Journal:  Mol Immunol       Date:  2019-06-10       Impact factor: 4.407

Review 5.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 6.  The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.

Authors:  Kimberly A Thomas; Nicole M Valenzuela; Elaine F Reed
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

Review 7.  Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification.

Authors:  Annalisa Angelini; Chiara Castellani; Marny Fedrigo; Onno J de Boer; Lorine B Meijer-Jorna; Xiaofei Li; Marialuisa Valente; Gaetano Thiene; Allard C van der Wal
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

8.  Comparative biology of decellularized lung matrix: Implications of species mismatch in regenerative medicine.

Authors:  Jenna L Balestrini; Ashley L Gard; Kristin A Gerhold; Elise C Wilcox; Angela Liu; Jonas Schwan; Andrew V Le; Pavlina Baevova; Sashka Dimitrievska; Liping Zhao; Sumati Sundaram; Huanxing Sun; Laure Rittié; Rachel Dyal; Tom J Broekelmann; Robert P Mecham; Martin A Schwartz; Laura E Niklason; Eric S White
Journal:  Biomaterials       Date:  2016-06-16       Impact factor: 12.479

9.  Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside.

Authors:  Carrie L Butler; Michelle J Hickey; Ning Jiang; Ying Zheng; David Gjertson; Qiuheng Zhang; Ping Rao; Gregory A Fishbein; Martin Cadeiras; Mario C Deng; Hector L Banchs; Guillermo Torre; David DeNofrio; Howard J Eisen; Jon Kobashigawa; Randall C Starling; Abdallah Kfoury; Adrian Van Bakel; Gregory Ewald; Ivan Balazs; Arnold S Baas; Daniel Cruz; Reza Ardehali; Reshma Biniwale; Murray Kwon; Abbas Ardehali; Ali Nsair; Bryan Ray; Elaine F Reed
Journal:  Am J Transplant       Date:  2020-04-26       Impact factor: 8.086

Review 10.  MHC class I signaling: new functional perspectives for an old molecule.

Authors:  E W Tsai; E F Reed
Journal:  Tissue Antigens       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.